CLINICAL TRIALS PROFILE FOR DALVANCE
✉ Email this page to a colleague
All Clinical Trials for Dalvance
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02269644 ↗ | A P3 Comparator Trial in Community Acquired Bacterial Pneumonia | Withdrawn | Durata Therapeutics Inc., an affiliate of Allergan plc | Phase 3 | 2015-11-01 | This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia. |
| NCT02344511 ↗ | Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis | Withdrawn | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Phase 3 | 2016-03-01 | Dalbavancin for Pediatric Osteomyelitis |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | Allergan | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | The Foundation for Barnes-Jewish Hospital | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| NCT03372941 ↗ | Hospital Avoidance Strategies for ABSSSI | Terminated | Washington University School of Medicine | Phase 4 | 2019-03-04 | More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dalvance
Condition Name
Clinical Trial Locations for Dalvance
Trials by Country
Clinical Trial Progress for Dalvance
Clinical Trial Phase
Clinical Trial Sponsors for Dalvance
Sponsor Name
